TIAA Trust National Association Has $12.87 Million Stock Holdings in Stryker Corporation $SYK

TIAA Trust National Association decreased its stake in Stryker Corporation (NYSE:SYK) by 7.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 32,532 shares of the medical technology company’s stock after selling 2,796 shares during the quarter. TIAA Trust National Association’s holdings in Stryker were worth $12,870,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SYK. Brighton Jones LLC boosted its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the last quarter. Golden State Wealth Management LLC grew its position in shares of Stryker by 24.1% in the 1st quarter. Golden State Wealth Management LLC now owns 247 shares of the medical technology company’s stock valued at $92,000 after acquiring an additional 48 shares during the period. Capital Investment Advisory Services LLC increased its stake in shares of Stryker by 11.9% during the 1st quarter. Capital Investment Advisory Services LLC now owns 3,193 shares of the medical technology company’s stock worth $1,189,000 after purchasing an additional 339 shares during the last quarter. World Investment Advisors increased its stake in shares of Stryker by 4.7% during the 1st quarter. World Investment Advisors now owns 11,088 shares of the medical technology company’s stock worth $4,128,000 after purchasing an additional 495 shares during the last quarter. Finally, Simmons Bank raised its holdings in shares of Stryker by 129.6% in the 1st quarter. Simmons Bank now owns 2,477 shares of the medical technology company’s stock valued at $922,000 after purchasing an additional 1,398 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research analyst reports. Needham & Company LLC lifted their price target on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. BTIG Research lifted their target price on Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a research note on Friday. Truist Financial decreased their target price on Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a report on Wednesday, October 15th. Wells Fargo & Company increased their price target on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Finally, Evercore ISI reduced their price objective on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday. Thirteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $434.16.

Stryker Trading Down 3.5%

Shares of Stryker stock opened at $356.15 on Monday. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The stock has a market cap of $136.16 billion, a PE ratio of 47.17, a PEG ratio of 2.66 and a beta of 0.94. The firm has a 50-day moving average of $378.08 and a 200-day moving average of $381.04. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the firm posted $2.87 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were issued a $0.84 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is currently 44.15%.

Insiders Place Their Bets

In related news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.